WebApr 10, 2024 · Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre … WebINCY Price $73.62 Fair Value Price $86.91 Market Cap $16.41B 52 Week Low $65.07 52 Week High $86.29 P/E 48.12x P/B 3.76x P/S 5.25x PEG 0.66x Dividend Yield N/A Revenue $3.39B Earnings $340.66M Gross Margin 93.9% Operating Margin 15.67% Profit Margin 10% Debt to Equity 0.34 Operating Cash Flow $970M Beta 0.72 Next Earnings May 1, 2024 Ex …
INCY - Incyte Corp Stock Price Quote - NASDAQ
WebMar 23, 2024 · Shares of Incyte have lost 6.3% in the past year compared with the industry ’s decline of 15.6%. Image Source: Zacks Investment Research Approval of additional drugs will add an incremental... WebApr 11, 2024 · Exchange Traded Concepts LLC decreased its position in Incyte Co. (NASDAQ:INCY - Get Rating) by 7.5% during the 4th quarter, according to the company in its most recent filing with the SEC. ... The company has a market cap of $16.48 billion, a price-to-earnings ratio of 48.64, a PEG ratio of 3.28 and a beta of 0.73. The company has a … phl terminal e
Incyte Corporation (INCY) Stock Price Today, Quote & News
WebApr 15, 2024 · The firm has a market cap of $16.61 billion, a PE ratio of 49.01, a price-to-earnings-growth ratio of 3.21 and a beta of 0.73. Incyte ( NASDAQ:INCY – Get Rating ) last released its quarterly ... WebApr 12, 2024 · The company has a market cap of $16.54 billion, a P/E ratio of 48.80, a price-to-earnings-growth ratio of 3.28 and a beta of 0.73. Incyte ( NASDAQ:INCY - Get Rating) last released its quarterly earnings results on Tuesday, February 7th. WebApr 10, 2024 · Market Cap $16.45B Shares Outstanding 222.97M Public Float 220.79M Beta 0.68 Rev. per Employee $1.461M P/E Ratio 49.62 EPS $1.52 Yield N/A Dividend N/A Ex-Dividend Date N/A Short Interest 6.53M... tsu country member s network株式会社